Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study
| Autor: | Didier Debieuvre, T. Payen, S. Larive, S. Hominal, L. Moreau, J.-L. Bizec, V. Grangeon, Olivier Molinier, J. Le Treut, C. Nocent, Jean Trédaniel |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology medicine.medical_specialty Lung Neoplasms Adolescent Phases of clinical research Erlotinib Hydrochloride Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Progression-free survival Epidermal growth factor receptor Stage (cooking) Lung cancer Performance status biology business.industry medicine.disease respiratory tract diseases ErbB Receptors Clinical Trials Phase III as Topic Mutation Cohort biology.protein Female Erlotinib business medicine.drug |
| Zdroj: | Respiratory Medicine and Research. 80:100795 |
| ISSN: | 2590-0412 |
| DOI: | 10.1016/j.resmer.2020.100795 |
| Popis: | Background Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS). Methods Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age ≥ 18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan–Meier method. Results A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0–1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS = 2, HR = 4.48, P Conclusions This study has confirmed erlotinib's efficacy and safety for unselected patients, with PFS and OS comparable to those obtained in phase III trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect